SCHLIEREN (ZURICH), Switzerland, May 29, 2018 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX:KURN) announced today the start of an investigator-led study at University Medical Center (UMC) Utrecht, using MagnetOs Granules for maxillary sinus floor elevation with two-stage implant placement. Sinus floor elevation is performed to allow placement of dental implants in the maxilla, or upper jaw. It is most commonly performed when the floor of the sinus is too close to an area where dental implants are to be inserted.
The prospective clinical trial will compare MagnetOs Granules to autologous bone (autograft), harvested from the patient’s own body, which is the current gold standard treatment. It is being conducted at the Department of Oral and Maxillofacial Surgery & Special Dentistry, UMC Utrecht and is designed as a controlled open-label, randomized non-inferiority trial with 30 patients. The primary outcome is assessment of effectiveness after 4-6 months. The first patients have already been treated.
Joost de Bruijn, Chief Executive Officer of Kuros, said: “We are very pleased to be taking part in this investigator-led study with the world-renowned Department of Oral and Maxillofacial Surgery at UMC Utrecht. There is a lot of interest from the clinical research community to study a variety of exciting applications in which our CE marked MagnetOs product can promote bone formation. These investigator-led studies expand the clinical evidence base of MagnetOs, and potentially support its positioning in additional therapeutic areas.”
Prof. Toine Rosenberg of the Dept. of Oral and Maxillofacial Surgery at UMC Utrecht, who is leading the study, said: “This is a valuable opportunity to assess promising osteoinductive granules that promote local bone formation, which could help make the delicate task of inserting dental implants easier and more successful. Success in this trial could have implications for multiple other potential applications.”
MagnetOs promotes local bone formation equivalent to current gold standard, autograft. MagnetOs is a bone graft substitute intended to fill bony voids or gaps of the human skeletal system and promote the formation of bone at the implanted site. A substantial number of clinically relevant and predictive studies have demonstrated its equivalence to the current gold standard (patient’s own bone, which may not be available in sufficient quantities and/or involves morbidity, costs and pain associated with its harvesting from another healthy site of the patient’s body). MagnetOs is a bone graft comprising biphasic calcium phosphate with an advanced submicron surface topography that directs bone formation after implantation. With its unique submicron surface topography, MagnetOs preferentially directs early wound healing toward the bone-forming pathway, resulting in an osteoinductive claim in Europe. MagnetOs is available as granules and as a putty formulation.
For further information, please contact:
Kuros Biosciences AG
Chief Financial Officer
Tel +41 44 733 47 47
Media & Investors
+41 79 598 7149
About Kuros Biosciences AG
Kuros Biosciences (SIX:KURN) is focused on the development of innovative products for bone regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. Visit www.kurosbio.com for additional information on Kuros, its people, science and product pipeline.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.